Introduction
============

Retinal vein occlusions (RVOs), including central retinal vein occlusion (CRVO), an occlusion at the central trunk of the retinal vein, and branch retinal vein occlusion (BRVO), an occlusion at an arteriovenous crossing where the retinal artery and vein are bound by a common adventitial sheath, are important causes of ocular morbidity \[[@r1],[@r2]\]. Although CRVO and BRVO have several risk factors in common, including systemic hypertension, smoking, hyperlipidemia, and elevated plasma homocysteine \[[@r1],[@r2]\], they do not fully explain the involvement of the central trunk or branch of the retinal vein circulation.

Exfoliation syndrome (EX), the most common identifiable cause of open-angle glaucoma worldwide, is an age-related, generalized disorder of the extracellular matrix characterized by the production and progressive accumulation of fibrillar extracellular material in many ocular tissues \[[@r3]\]. A recent genome-wide association study reported that one intronic single nucleotide polymorphism (SNP; [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241)) and two exonic SNPs ([rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661) \[R141L\], [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942) \[G153D\]) in the first exon of the lysyl oxidase-like 1 *(LOXL1)* gene on chromosome 15q24.1 are highly associated with EX in Icelandic and Swedish populations, and that none of these SNPs was associated with primary open-angle glaucoma in the two populations \[[@r4]\]. Several studies have confirmed the association of these SNPs with EX in other populations \[[@r5]\], including a Japanese population \[[@r6]-[@r11]\].

In addition to ocular tissues, production and progressive accumulation of exfoliation materials occur in skin and various visceral organs \[[@r3],[@r12]\]. The association of EX with various systemic vascular and neurodegenerative disorders has been described in ischemic heart disease \[[@r13],[@r14]\], carotid stiffness \[[@r15]\], cerebrovascular disease \[[@r16]\], Alzheimer disease \[[@r17]\], and hearing loss \[[@r18]\]. Regarding RVO, several studies have described a possible association between CRVO and EX diagnosed based on chart review \[[@r19]\], slit-lamp examination \[[@r20]\], histopathologic studies in enucleated eyes \[[@r21],[@r22]\], and a combination of slit-lamp examination and conjunctival biopsy \[[@r23]\], while only a few studies have evaluated the association between BRVO and EX \[[@r19],[@r20]\]. Recently, the role of the *LOXL1* polymorphism has been tested in several ocular \[[@r24]\] and systemic \[[@r25],[@r26]\] pathologies to explore the association between EX and these pathologies, suggesting the usefulness of analyzing *LOXL1* variants as a disease marker for EX.

In the current study, we tested the association between *LOXL1* variants and BRVO in a Japanese population to explore a possible association between EX and BRVO.

Methods
=======

Subjects
--------

Unrelated Japanese subjects with BRVO (n=78) were consecutively recruited at the Shimane University Hospital and Iinan Hospital in Shimane, Japan. The BRVO group was divided into two subgroups based on the presence (EX+, n=11) or absence (EX-, n=67) of clinically detectable ocular deposits of exfoliation material. The data set from patients with cataract without deposits of exfoliation material (CT, n=158) reported in our previous study \[[@r11]\] served as a control. The demographic data including age and gender for each group are summarized in [Table 1](#t1){ref-type="table"}.

###### Summary of study populations.

  ** **             **BRVO**   ** **    ** **                 
  ----------------- ---------- -------- ---------- ---------- --------------
  No. of subjets    78         67       11         158         
  **Men/Women**                                               
  No.               32/46      29/38    3/8        45/113     0.0568\*
  \%                41/59      33/67    27/73      28/72       
  **Age (years)**                                             
  Mean±SD           73.2±9.6   72±9.4   80.5±6.8   76.9±4.9   5.81×10^−5^†
  Range             47--88     47--87   69--88     70--90      

\*Fisher's exact probability test between BRVO (total) and CT groups. †Unpaired *t*-test between BRVO (total) and CT groups.

Methods
-------

The current study adhered to the tenets of the Declaration of Helsinki. The institutional review boards of both hospitals reviewed and approved the research. All subjects provided written informed consent. All subjects underwent a dilated pupil examination of the anterior segments, ocular media, and fundus using a slit-lamp (RO5000, Buchmann Deutschland, Düsseldorf, Germany) and a funduscope (BS-III, Neitz Instruments, Tokyo, Japan). BRVO was diagnosed if the fundus examination revealed venous dilation and tortuosity with flame-shaped and dot-blot hemorrhages in a wedge-shaped region. Patients with CRVO and hemi-CRVO were excluded. Deposits of exfoliation material were identified if the slit-lamp examination revealed a typical pattern of exfoliation material on the anterior lens surface and/or pupillary margin.

DNA genotyping
--------------

Genomic DNA was extracted from the peripheral white blood cells of each subject. A polymerase chain reaction was performed using primers designed to amplify the genomic region containing both [rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661) and [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942) (forward primer: 5′-AGG TGT ACA GCT TGC TCA ACT C-3′ and reverse primer: 5′-TAG TAC ACG AAA CCC TGG TCG T-3′) or only [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241) (forward primer: 5′-AGA ATG CAA GAC CTC AGC ATG AG-3′ and reverse primer: 5′-TAG TGG CCA GAG GTC TGC TAA G-3′). The sequence was determined based on the dideoxy terminator method using an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. We used SeqScape Software version 2.5 (Applied Biosystems) to analyze the sequence alignment.

Statistical analysis
--------------------

Statistical analysis was performed using R version 2.6.2. Fisher's exact test was used to compare the allele or genotype frequencies of each group with the controls.

Results
=======

The allelic and genotypic counts and frequencies of SNPs [rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661), [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942), and [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241) within *LOXL1* are shown in [Table 2](#t2){ref-type="table"}. Compared to the CT group, the T allele and TT genotype frequencies of [rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661) were higher in patients with BRVO (p=0.0137 and p=0.0203, respectively). In subgroup analysis, compared to the CT group, the group with BRVO with exfoliation material deposits (EX+) had significantly different allelic and genotypic frequencies (p=0.00011 and p=0.000189, respectively), while the group with BRVO without exfoliation material deposits (EX-) had no difference in allelic and genotypic frequencies (p=0.175 and p=0.288, respectively). Compared to the CT group, the frequencies of the G allele of [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942) and the C allele of [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241) were higher in the BRVO EX+ groups with borderline significance (p=0.0933 and p=0.0908, respectively), but the allelic and genotypic frequencies did not differ between any pairs of BRVO total or BRVO EX- and the CT group.

###### Allelic and genotypic counts and frequencies of SNPs [rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661), [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942), and [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241).

  ** **                                                                          **BRVO**   ** **   ** **   ** **   ** **   ** **                                  
  ------------------------------------------------------------------------------ ---------- ------- ------- ------- ------- ------- ----- ------- -------- ------- -------------
  [rs1048661](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1048661)                                                                                     
  **Allele**                                                                                                                                                       
  T                                                                              86         0.566   67      0.515   19      0.864   140   0.443   0.0137   0.175   1.10×10^−4^
  G                                                                              66         0.434   63      0.485   3       0.136   176   0.557   ** **    ** **   ** **
  **Genotype**                                                                                                                                                     
  TT                                                                             24         0.316   16      0.246   8       0.727   25    0.158   0.0203   0.288   1.89×10^−4^
  TG                                                                             38         0.500   35      0.538   3       0.273   90    0.570   ** **    ** **   ** **
  GG                                                                             14         0.184   14      0.215   0       0       43    0.272   ** **    ** **   ** **
  [rs3825942](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3825942)                                                                                     
  **Allele**                                                                                                                                                       
  G                                                                              131        0.862   110     0.846   21      0.955   255   0.807   0.155    0.348   0.0933
  A                                                                              21         0.138   20      0.154   1       0.045   61    0.193   ** **    ** **   ** **
  **Genotype**                                                                                                                                                     
  GG                                                                             57         0.750   47      0.723   10      0.909   101   0.639   0.212    0.424   0.209
  AG                                                                             17         0.224   16      0.246   1       0.091   53    0.335   ** **    ** **   ** **
  AA                                                                             2          0.026   2       0.031   0       0       4     0.025   ** **    ** **   ** **
  [rs2165241](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2165241)                                                                                     
  **Allele**                                                                                                                                                       
  C                                                                              135        0.877   113     0.856   22      1.000   277   0.877   1        0.541   0.0908
  T                                                                              19         0.123   19      0.144   0       0       39    0.123   ** **    ** **   ** **
  **Genotype**                                                                                                                                                     
  CC                                                                             61         0.792   50      0.758   11      1.000   123   0.778   0.765    0.685   0.335
  CT                                                                             13         0.169   13      0.197   0       0       31    0.196   ** **    ** **   ** **
  TT                                                                             3          0.039   3       0.045   0       0       4     0.025   ** **    ** **   ** **

\*Fisher\'s exact probability test.

Discussion
==========

To the best of our knowledge, this is the first study to identify a possible association between *LOXL1* variants and BRVO. The prevalence of clinical EX increases with age, especially after age 60 \[[@r3]\]. Accordingly, detection of exfoliation material deposits by slit-lamp examination may overlook latent EX. Indeed, previous studies have suggested that the prevalence of exfoliation material deposits found on histopathologic assessment of ocular specimens was roughly double compared with the slit-lamp examination \[[@r27],[@r28]\]. A conjunctival biopsy can detect preclinical EX that is not evident on slit-lamp examination \[[@r23]\]; however, because the biopsy is invasive, it cannot be used for all patients. The role of the *LOXL1* polymorphism has been tested in several pathologies including wet and dry age-related macular degeneration and polypoidal choroidal vasculopathy in a Japanese population \[[@r24]\], Alzheimer disease in a Swedish population \[[@r25]\], and cardiovascular disease in a Hungarian population \[[@r26]\]. Fuse et al. found a significant association between the [rs1048661](http://www.ncbi.nlm.nih.gov/snp?term=rs1048661) polymorphism and wet age-related macular degeneration in a Japanese population \[[@r24]\]. These studies encouraged us to use the *LOXL1* polymorphism as an alternative marker of clinically undetectable EX other than invasive biopsy/histopathology.

Among the three SNPs reported \[[@r4]\], [rs1048661](http://www.ncbi.nlm.nih.gov/snp?term=rs1048661) has been consistently suggested as the most significant indicator of EX/glaucoma in Icelandic, Swedish, and Japanese populations \[[@r6]-[@r11]\]. Accordingly, our results of a significant difference in allelic and genotypic frequencies of [rs1048661](http://www.ncbi.nlm.nih.gov/snp?term=rs1048661) between all subjects with BRVO and CT or BRVO EX+ and CT groups confirmed previous observations of the strong role of this SNP in EX. The results also suggested that using this SNP, we can detect a case--control association for EX even with such a small number of subjects (n=11) in a case group. In the same context, the other two SNPs, which showed only a borderline difference between BRVO EX+ and CT groups, may not have enough discriminatory power with this small number of subjects.

Since both the BRVO EX- and CT groups, which were classified based on slit-lamp examination as not having EX, were identical except for the presence or absence of BRVO, comparison between these two groups should provide the most reliable information about the possible role of the *LOXL1* variants in BRVO. As a result, the significant difference observed in [rs1048661](http://www.ncbi.nlm.nih.gov/snp?term=rs1048661) between the case and control groups was canceled in the analyses between the BRVO EX- and CT groups, suggesting that the percentage of the population at risk of EX is not significantly higher in the BRVO group. A retrospective chart review reported exfoliation material deposits in 6.0% of eyes with BRVO and 6.9% of eyes with CRVO \[[@r19]\], suggesting a lesser extent of BRVO than CRVO in these subjects, since the BRVO/CRVO ratio was 3.2 in the general population \[[@r29]\]. By clinical observation of consecutive cases, the prevalence rates of EX were 8.2% in eyes with BRVO and 20.8% in eyes with CRVO compared with 5.2% in control eyes; thus the authors concluded that EX is likely a risk factor for CRVO \[[@r20]\]. A retrospective chart review showed that RVO occurs more frequently in eyes more affected by EX, and that the most frequent type of RVO that occurred in EX was CRVO (50%) followed by about half that prevalence of BRVO (28%) \[[@r23]\]. In this study, the prevalence rate of EX was 14% in eyes with BRVO from consecutive cases, which may be higher than the rate of EX in BRVO cases and normal control subjects in previous reports \[[@r19],[@r20]\]. Differences in the race or age of subjects may explain the discrepancy, but this needs to be clarified. Taken together with previous studies, our results suggest that there is no direct role of *LOXL1* variants or EX in the development of BRVO in our Japanese subjects.

In summary, we tested the possible association of *LOXL1* variants with BRVO. We did not find an association between BRVO and EX if the *LOXL1* variants were used as disease markers for clinically undetectable EX.
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